• GPR35–KLF5 Circuitry in Epithelial Repair

  2026-10-05

  A 2026 Cell Death and Disease study identifies a tryptophan-metabolite sensing mechanism in which GPR35 connects mucosal damage signals to KLF5-dependent epithelial repair. The findings position the GPR35–KLF5 axis as a mechanistic framework for ulcerative colitis research while remaining preclinical and model-dependent.

• JHU-083: Evidence, Context, and Research Limits

  2026-10-05

  JHU-083 is described by APExBIO as a 6-diazo-5-oxo-L-norleucine precursor and selective glutaminase antagonist for research involving cerebral CD11b cells and experimental cerebral malaria. This overview separates that supplier-level description from peer-reviewed evidence supplied for a distinct α-amanitin liver-injury study. It explains the proposed relevance to glutaminase pathway research, glutamate biology, and neurological disease models while emphasizing the absence of independent JHU-083 efficacy data, human evidence, and direct support for therapeutic or cross-organ conclusions.

• Haloprogin: Evidence from a 1970 Topical Study

  2026-10-04

  Harrison and colleagues showed that Haloprogin combined dermatophyte activity comparable to tolnaftate with additional activity against Candida species and selected Gram-positive bacteria. The study’s value lies in connecting comparative in vitro testing with a topical guinea pig model, while its age, limited organism coverage, and lack of molecular-mechanism data constrain modern interpretation.

• Sunitinib: Five Questions About the Evidence

  2026-10-03

  A source-grounded overview of Sunitinib, RTK inhibition, ATRX-deficient glioma findings, evidence quality, interpretation, applicability, and key limitations.

• Sisomicin Activity Against Clinical Isolates

  2026-10-02

  This historical study compared sisomicin with gentamicin, tobramycin, amikacin, butirosin, and kanamycin across 565 clinical isolates. Its main contribution was a structured, head-to-head MIC assessment showing broad activity against Gram-negative bacilli, while also revealing cross-resistance between sisomicin and gentamicin or tobramycin.

• ASB5 in Muscle Satellite Cells: Marker, Not Driver

  2026-10-01

  The reference study identifies ASB5 as a highly specific marker of muscle satellite cells and myogenic progenitors while showing that Asb5 is dispensable for normal skeletal muscle development, growth, regeneration, and satellite-cell behavior. Its combination of single-cell transcriptomics, CRISPR-Cas9 knockout, myofiber assays, injury analysis, and qPCR provides a useful framework for separating cell-state markers from essential regulators.

• THZ1: Covalent CDK7 Inhibition

  2026-10-01

  THZ1 is a covalent CDK7 inhibitor that irreversibly modifies CDK7 C312 and suppresses RNA polymerase II C-terminal-domain phosphorylation. Its reported biochemical and T-cell acute lymphoblastic leukemia (T-ALL) activity supports focused transcriptional and cancer biology research, but the compound remains a research-use reagent rather than a clinical treatment.

• Computational Hapten Design for Amatoxin Biosensing

  2026-09-30

  The 2026 reference study combines molecular similarity analysis, quantum chemistry, and monoclonal antibody engineering to improve simultaneous recognition of amatoxins and phallotoxins. Its dual-target fluorescent immunochromatographic assay achieved low microgram-per-kilogram detection limits in mushroom matrices, supporting rapid screening where laboratory mass spectrometry is impractical.

• Bafilomycin C1 in High-Content Cell Assays

  2026-09-30

  Bafilomycin C1 converts lysosomal acidification into a controllable phenotypic perturbation for autophagy assays, iPSC-cardiomyocyte imaging, and mechanistic toxicity studies. This workflow explains how to dose, image, analyze, and troubleshoot the compound without mistaking organelle stress for primary cardiotoxicity.

• Machine-Learning Discovery of Senolytic Compounds

  2026-09-29

  The reference study shows that machine-learning models trained only on published screening data can prioritize senolytic candidates despite limited and heterogeneous datasets. Computational screening followed by human-cell validation identified ginkgetin, periplocin, and oleandrin, establishing a lower-cost route for early senolytic discovery while highlighting important limits in assay transferability and selectivity.

• AZ 10417808 in ATRX-Deficient Glioma

  2026-09-29

  Explore how AZ 10417808 can be evaluated in ATRX-deficient glioma research through genotype-aware assay design, RTK/PDGFR biology, and combination testing with temozolomide. This evidence-focused guide emphasizes what the literature supports and which conclusions require direct validation.

• Nigericin: Translating Ion Gradients into Strategy

  2026-09-28

  Nigericin is more than a membrane-active antibiotic: it is a controllable potassium/hydrogen ion carrier that turns intracellular pH and mitochondrial ion transport into experimental variables. This thought-leadership guide connects its mechanism with anticancer assay design, GSDMD-linked cellular pyrokinesis, and a carefully bounded hypothesis for metabolism-informed antimicrobial research.

• Haloprogin: Applied Antifungal Research Workflows

  2026-09-28

  Haloprogin offers a useful research tool for comparing dermatophyte, Candida, and selected Gram-positive responses in matched in vitro and topical infection workflows. This guide turns published assay conditions and product data into practical steps for dilution testing, fungicidal confirmation, formulation studies, and troubleshooting.

• Haloprogin BA1790: Practical Antimicrobial Assays

  2026-09-27

  A scenario-based guide to using Haloprogin (SKU BA1790) in antimicrobial assays, with MIC benchmarks, solvent and storage considerations, and interpretation limits. It distinguishes antimicrobial susceptibility evidence from cell viability assay validation so researchers can design clearer, more reproducible experiments.

• Anti-ROR1 Antibody: Practical Assay Workflows

  2026-09-26

  Build binding, flow-cytometry, and functional workflows around Zilovertamab, with practical controls that separate target engagement from downstream effects. The article also puts a DON liver-injury study in context: it offers useful experimental-design lessons, not evidence that ROR1 drives toxin-induced liver injury.

8178 records 1/546 page Next 12345 下5页 Last page